Paul Coley
Pulmonary Disease · Jacksonville, FLNPI 1962468892
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by GSK at 33.3% of the total. Reporting peaked in 2019 at $2,023 and has fallen 98.9% since, to $22 in 2021. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 125 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$716
- AstraZeneca$347
- Grifols USA, LLC$225
- Philips North America LLC$140
- Sunovion Pharmaceuticals Inc.$133
- Mylan Specialty L.p.$71
- plus $516 from 16 others
Across 4 payments — averaging $52,124 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$208K
What the payments were for
- Food & beverage$2,148100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 43 | $716 |
| AstraZeneca | 16 | $347 |
| Grifols USA, LLC | 11 | $225 |
| Philips North America LLC | 12 | $140 |
| Sunovion Pharmaceuticals Inc. | 9 | $133 |
| Mylan Specialty L.p. | 3 | $71 |
| Boehringer Ingelheim | 4 | $70 |
| Regeneron Healthcare Solutions, Inc. | 2 | $69 |
| AbbVie | 4 | $52 |
| Merck | 3 | $46 |
| Electromed, Inc. | 3 | $44 |
| Mallinckrodt Enterprises LLC | 2 | $37 |
| Genentech USA, Inc. | 2 | $35 |
| Insmed, Inc. | 2 | $34 |
| Circassia Inc. | 2 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Optinose US, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Portola Pharmaceuticals, LLC | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
| Pfizer | 1 | $11 |
| Bayer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$125
- FASENRA$103
How this compares
$2,148 in reported general payments places this provider in the 40th percentile of 953 pulmonary disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azithromycin | 13 | $71 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Jacksonville
- Jennifer FultonJacksonville$665K
- Jose Soto SotoJacksonville$504K
- Jorge MalleaJacksonville$457K
- Abubakr BajwaJacksonville$414K
- Bryan HustaJacksonville$283K
- Sebastian Fernandez-BussyJacksonville$257K
- Peter NassarJacksonville$141K
- Charles BurgerJacksonville$124K
- Daniel WyzanJacksonville$100K
- David Abia TrujilloJacksonville$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.